Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N.

Science. 2010 Oct 8;330(6001):228-31. doi: 10.1126/science.1196333. Epub 2010 Sep 8.

PMID:
20826764
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

ARID1A mutations in endometriosis-associated ovarian carcinomas.

Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IeM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG.

N Engl J Med. 2010 Oct 14;363(16):1532-43. doi: 10.1056/NEJMoa1008433. Epub 2010 Sep 8.

PMID:
20942669
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.

Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.

Virchows Arch. 2012 Jan;460(1):77-87. doi: 10.1007/s00428-011-1169-8. Epub 2011 Nov 26.

PMID:
22120431
[PubMed - indexed for MEDLINE]
4.

PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.

Rahman M, Nakayama K, Rahman MT, Nakayama N, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Otsuki Y, Nakayama S, Miyazaki K.

Anticancer Res. 2013 Jan;33(1):113-8.

PMID:
23267135
[PubMed - indexed for MEDLINE]
5.

ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.

Guan B, Wang TL, Shih IeM.

Cancer Res. 2011 Nov 1;71(21):6718-27. doi: 10.1158/0008-5472.CAN-11-1562. Epub 2011 Sep 7. Erratum in: Cancer Res. 2012 Jun 15;72(12):3116.

PMID:
21900401
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.

Samartzis EP, Noske A, Dedes KJ, Fink D, Imesch P.

Int J Mol Sci. 2013 Sep 12;14(9):18824-49. doi: 10.3390/ijms140918824. Review.

PMID:
24036443
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions.

Guan B, Gao M, Wu CH, Wang TL, Shih IeM.

Neoplasia. 2012 Oct;14(10):986-93.

PMID:
23097632
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer.

Oike T, Ogiwara H, Nakano T, Yokota J, Kohno T.

Jpn J Clin Oncol. 2013 Sep;43(9):849-55. doi: 10.1093/jjco/hyt101. Epub 2013 Jul 30.

PMID:
23904343
[PubMed - indexed for MEDLINE]
Free Article
9.

Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.

Wu RC, Ayhan A, Maeda D, Kim KR, Clarke BA, Shaw P, Chui MH, Rosen B, Shih IeM, Wang TL.

J Pathol. 2014 Mar;232(4):473-81. doi: 10.1002/path.4315.

PMID:
24338723
[PubMed - indexed for MEDLINE]
10.

Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.

Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.

Mod Pathol. 2012 Apr;25(4):615-24. doi: 10.1038/modpathol.2011.189. Epub 2011 Dec 9.

PMID:
22157930
[PubMed - indexed for MEDLINE]
Free Article
11.

Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types.

Jones S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D, Hruban RH, Eshleman JR, Iacobuzio-Donahue CA, Goggins M, Maitra A, Malek SN, Powell S, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N.

Hum Mutat. 2012 Jan;33(1):100-3. doi: 10.1002/humu.21633. Epub 2011 Nov 23.

PMID:
22009941
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.

Le Gallo M, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ, Price JC, Zhang S, England BM, Godwin AK, Sgroi DC; NIH Intramural Sequencing Center (NISC) Comparative Sequencing Program, Hieter P, Mullikin JC, Merino MJ, Bell DW.

Nat Genet. 2012 Dec;44(12):1310-5. doi: 10.1038/ng.2455. Epub 2012 Oct 28.

PMID:
23104009
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

PIK3CA gene mutations and amplifications in Chinese patients with ovarian clear cell carcinoma.

Jiang G, Huang Z, Zhang S, Wang L.

Cancer Invest. 2013 Dec;31(10):639-44. doi: 10.3109/07357907.2013.853075.

PMID:
24299208
[PubMed - indexed for MEDLINE]
14.

[Tumor suppressor role of chromatin-remodeling factor ARID1A].

Guo XQ, Zhang QX, Huang WR, Duan XL, Cai ZM.

Yi Chuan. 2013 Mar;35(3):255-61. Review. Chinese.

PMID:
23575531
[PubMed - indexed for MEDLINE]
15.

Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.

Wu CH, Mao TL, Vang R, Ayhan A, Wang TL, Kurman RJ, Shih IeM.

Int J Gynecol Pathol. 2012 Jul;31(4):297-303. doi: 10.1097/PGP.0b013e31823f8482.

PMID:
22653341
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.

Katagiri A, Nakayama K, Rahman MT, Rahman M, Katagiri H, Nakayama N, Ishikawa M, Ishibashi T, Iida K, Kobayashi H, Otsuki Y, Nakayama S, Miyazaki K.

Mod Pathol. 2012 Feb;25(2):282-8. doi: 10.1038/modpathol.2011.161. Epub 2011 Nov 18.

PMID:
22101352
[PubMed - indexed for MEDLINE]
Free Article
17.

Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.

McConechy MK, Anglesio MS, Kalloger SE, Yang W, Senz J, Chow C, Heravi-Moussavi A, Morin GB, Mes-Masson AM; Australian Ovarian Cancer Study Group, Carey MS, McAlpine JN, Kwon JS, Prentice LM, Boyd N, Shah SP, Gilks CB, Huntsman DG.

J Pathol. 2011 Apr;223(5):567-73. doi: 10.1002/path.2848. Epub 2011 Mar 7.

PMID:
21381030
[PubMed - indexed for MEDLINE]
18.

ARID1A mutations in cancer: another epigenetic tumor suppressor?

Wu JN, Roberts CW.

Cancer Discov. 2013 Jan;3(1):35-43. doi: 10.1158/2159-8290.CD-12-0361. Epub 2012 Dec 3. Review.

PMID:
23208470
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.

Bosse T, ter Haar NT, Seeber LM, v Diest PJ, Hes FJ, Vasen HF, Nout RA, Creutzberg CL, Morreau H, Smit VT.

Mod Pathol. 2013 Nov;26(11):1525-35. doi: 10.1038/modpathol.2013.96. Epub 2013 May 24.

PMID:
23702729
[PubMed - indexed for MEDLINE]
Free Article
20.

Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.

Rahman M, Nakayama K, Rahman MT, Nakayama N, Ishikawa M, Katagiri A, Iida K, Nakayama S, Otsuki Y, Shih IeM, Miyazaki K.

Hum Pathol. 2012 Dec;43(12):2197-206. doi: 10.1016/j.humpath.2012.03.011. Epub 2012 Jun 15.

PMID:
22705003
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk